Tnfsf11

Summary

Gene Symbol: Tnfsf11
Description: tumor necrosis factor (ligand) superfamily, member 11
Alias: Ly109l, ODF, OPG, OPGL, RANKL, Trance, OPG ligand, TNF-related activation-induced cytokine, osteoclast differentiation factor, osteoprotegerin ligand, receptor activator of NF-kappaB ligand, receptor activator of nuclear factor kappa B ligand, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor ligand superfamily member 11, tumor necrosis factor-related activation-induced cytokine
Species: mouse

Top Publications

  1. ncbi Targeted deletion of the osteoclast protein-tyrosine phosphatase (PTP-oc) promoter prevents RANKL-mediated osteoclastic differentiation of RAW264.7 cells
    Jeannie H Yang
    Musculoskeletal Disease Center, Jerry L Pettis Memorial VA Medical Center, 11201 Benton Street, Loma Linda, CA 92357, USA
    FEBS Lett 581:2503-8. 2007
  2. ncbi Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
    D L Lacey
    Department of Pathology, Amgen, Inc, Thousand Oaks, California 91320 1789, USA
    Cell 93:165-76. 1998
  3. ncbi Regulation of cancer cell migration and bone metastasis by RANKL
    D Holstead Jones
    IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Dr Bohr Gasse 3, A 1030 Vienna, Austria
    Nature 440:692-6. 2006
  4. ncbi The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance
    Taishin Akiyama
    Division of Cellular and Molecular Biology, Institute of Medical Science, University of Tokyo, 4 6 1 Shirokane dai, Minato ku, Tokyo 108 8639, Japan
    Immunity 29:423-37. 2008
  5. ncbi RANK-RANKL signaling pathway is critically involved in the function of CD4+CD25+ regulatory T cells in chronic colitis
    Teruji Totsuka
    Department of Gastroenterology and Hepatology, Graduate School, Tokyo Medical and Dental University, Tokyo
    J Immunol 182:6079-87. 2009
  6. ncbi Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
    H Yasuda
    Research Institute of Life Science, Snow Brand Milk Products Co, Ltd, 519 Ishibashi machi, Shimotsuga gun, Tochigi 329 0512, Japan
    Proc Natl Acad Sci U S A 95:3597-602. 1998
  7. ncbi OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
    Y Y Kong
    Amgen Institute, Department of Medical Biophysics, University of Toronto, Ontario, Canada
    Nature 397:315-23. 1999
  8. ncbi Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
    Y Y Kong
    Amgen Institute, Toronto, Ontario, Canada
    Nature 402:304-9. 1999
  9. ncbi Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL
    Dominique D Pierroz
    Service of Bone Diseases, Department of Rehabilitation and Geriatrics, Geneva University Hospital and Faculty of Medicine, 1211 Geneva 14, Switzerland
    J Biol Chem 285:28164-73. 2010
  10. ncbi Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro
    Gary J Spencer
    Biomedical Tissue Research, Department of Biology, University of York, PO Box 373, York, YO10 5YW, UK
    J Cell Sci 119:1283-96. 2006

Research Grants

  1. BONE MATRIX AND BONE RESORPTION
    Paul R Odgren; Fiscal Year: 2010
  2. BONE MATRIX AND BONE RESORPTION
    PAUL ODGREN; Fiscal Year: 2006
  3. SACRAL CREST CELLS AND ENTERIC NEURODEVELOPMENT
    Raj Kapur; Fiscal Year: 2005
  4. TRANCE REGULATION OF CHONDROCYTE MATURATION
    PAUL ODGREN; Fiscal Year: 2005
  5. Combinatorial Protein Transfer for Cancer Therapeutics
    Aoshuang Chen; Fiscal Year: 2006
  6. MOLECULAR CONTROL OF RANKL GENE EXPRESSION
    CHARLES O BRIEN; Fiscal Year: 2007
  7. MOLECULAR CONTROL OF RANKL GENE EXPRESSION
    CHARLES A O apos BRIEN; Fiscal Year: 2010
  8. BONE MATRIX AND BONE RESORPTION
    PAUL ODGREN; Fiscal Year: 2009
  9. MOLECULAR CONTROL OF RANKL GENE EXPRESSION
    CHARLES O BRIEN; Fiscal Year: 2009
  10. Individual Predoctoral Dental Scientist Fellowship
    Cameron Walker; Fiscal Year: 2007

Scientific Experts

Detail Information

Publications114 found, 100 shown here

  1. ncbi Targeted deletion of the osteoclast protein-tyrosine phosphatase (PTP-oc) promoter prevents RANKL-mediated osteoclastic differentiation of RAW264.7 cells
    Jeannie H Yang
    Musculoskeletal Disease Center, Jerry L Pettis Memorial VA Medical Center, 11201 Benton Street, Loma Linda, CA 92357, USA
    FEBS Lett 581:2503-8. 2007
    ..The inability of PTP-oc-deficient RAW264.7 cells to undergo RANKL-mediated osteoclastic differentiation confirmed a regulatory role for PTP-oc in RANKL-mediated osteoclast ..
  2. ncbi Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
    D L Lacey
    Department of Pathology, Amgen, Inc, Thousand Oaks, California 91320 1789, USA
    Cell 93:165-76. 1998
    ..b>OPG ligand (OPGL) binds to a unique hematopoeitic progenitor cell that is committed to the osteoclast lineage and ..
  3. ncbi Regulation of cancer cell migration and bone metastasis by RANKL
    D Holstead Jones
    IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Dr Bohr Gasse 3, A 1030 Vienna, Austria
    Nature 440:692-6. 2006
    ..Here we show that the cytokine RANKL (receptor activator of NF-kappaB ligand) triggers migration of human epithelial cancer cells and melanoma cells ..
  4. ncbi The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance
    Taishin Akiyama
    Division of Cellular and Molecular Biology, Institute of Medical Science, University of Tokyo, 4 6 1 Shirokane dai, Minato ku, Tokyo 108 8639, Japan
    Immunity 29:423-37. 2008
    ..These results show that developmental-stage-dependent cooperation between RANK and CD40 promotes mTEC development, thereby establishing self-tolerance...
  5. ncbi RANK-RANKL signaling pathway is critically involved in the function of CD4+CD25+ regulatory T cells in chronic colitis
    Teruji Totsuka
    Department of Gastroenterology and Hepatology, Graduate School, Tokyo Medical and Dental University, Tokyo
    J Immunol 182:6079-87. 2009
    ..In this study, we demonstrate that the TNF family molecule RANKL and its receptor RANK are critically involved in controlling the function of CD4(+)CD25(+) T(R) cells in the ..
  6. ncbi Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
    H Yasuda
    Research Institute of Life Science, Snow Brand Milk Products Co, Ltd, 519 Ishibashi machi, Shimotsuga gun, Tochigi 329 0512, Japan
    Proc Natl Acad Sci U S A 95:3597-602. 1998
    ..We conclude that the membrane-bound protein is osteoclast differentiation factor (ODF), a long-sought ligand mediating an essential signal to osteoclast progenitors for their ..
  7. ncbi OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
    Y Y Kong
    Amgen Institute, Department of Medical Biophysics, University of Toronto, Ontario, Canada
    Nature 397:315-23. 1999
    ..ligand (OPGL; also known as TRANCE, RANKL and ODF) has been identified as a potential osteoclast differentiation factor and regulator of interactions between T cells and dendritic cells in vitro...
  8. ncbi Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
    Y Y Kong
    Amgen Institute, Toronto, Ontario, Canada
    Nature 402:304-9. 1999
    ..remodelling and bone loss are controlled by a balance between the tumour necrosis factor family molecule osteoprotegerin ligand (OPGL) and its decoy receptor osteoprotegerin (OPG)...
  9. ncbi Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL
    Dominique D Pierroz
    Service of Bone Diseases, Department of Rehabilitation and Geriatrics, Geneva University Hospital and Faculty of Medicine, 1211 Geneva 14, Switzerland
    J Biol Chem 285:28164-73. 2010
    PTH stimulates osteoblastic cells to form new bone and to produce osteoblast-osteoclast coupling factors such as RANKL. Whether osteoclasts or their activity are needed for PTH anabolism remains uncertain...
  10. ncbi Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro
    Gary J Spencer
    Biomedical Tissue Research, Department of Biology, University of York, PO Box 373, York, YO10 5YW, UK
    J Cell Sci 119:1283-96. 2006
    ..repression of the gene encoding the osteoclastogenic cytokine receptor activator of NFkappaB ligand (RANKL or TNFSF11) expressed by osteoblasts...
  11. ncbi Activation of extracellular signal-regulated kinase is involved in mechanical strain inhibition of RANKL expression in bone stromal cells
    Janet Rubin
    Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
    J Bone Miner Res 17:1452-60. 2002
    ..In vitro, application of strain inhibits osteoclast formation by decreasing expression of the ligand RANKL in bone stromal cells, but the mechanism responsible for this down-regulation is unknown...
  12. ncbi TRAF5 functions in both RANKL- and TNFalpha-induced osteoclastogenesis
    Kiyoshi Kanazawa
    Department of Life Science, Tokyo Institute of Technology, Yokohama, Japan
    J Bone Miner Res 18:443-50. 2003
    Although TRAF6 is essential for both RANKL- and TNFalpha-induced osteoclastogenesis, it has remained unclear whether other members of the TRAF family are involved in osteoclastogenesis...
  13. ncbi Mechanical strain differentially regulates endothelial nitric-oxide synthase and receptor activator of nuclear kappa B ligand expression via ERK1/2 MAPK
    Janet Rubin
    Department of Medicine, Veterans Affairs Medical Center and Emory University School of Medicine, Atlanta, Georgia 30033, USA
    J Biol Chem 278:34018-25. 2003
    ..nitric-oxide synthase (eNOS), prevents resorption, whereas receptor activator of nuclear kappa B ligand (RANKL) promotes resorption through regulating osteoclast activity...
  14. ncbi MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL
    Conor C Lynch
    Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee 37232, USA
    Cancer Cell 7:485-96. 2005
    ..MMP-7, which was produced by osteoclasts at the tumor-bone interface, was capable of processing RANKL to a soluble form that promoted osteoclast activation...
  15. ncbi IL-1 mediates TNF-induced osteoclastogenesis
    Shi Wei
    Department of Pathology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Clin Invest 115:282-90. 2005
    TNF-induced receptor activator NF-kappaB ligand (RANKL) synthesis by bone marrow stromal cells is a fundamental component of inflammatory osteolysis...
  16. ncbi Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis
    Nacksung Kim
    Medical Research Center for Gene Regulation, Chonnam National University Medical School, Gwangju, Korea
    J Exp Med 202:589-95. 2005
    ..factors, including the tumor necrosis factor (TNF) family member TNF-related activation-induced cytokine (TRANCE)...
  17. ncbi TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
    K Fuller
    St George s Hospital Medical School, London, United Kingdom
    J Exp Med 188:997-1001. 1998
    b>TRANCE (tumor necrosis factor-related activation-induced cytokine) is a recently described member of the tumor necrosis factor superfamily that stimulates dendritic cell survival and has also been found to induce osteoclastic ..
  18. ncbi TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor
    B R Wong
    Laboratory of Immunology, The Rockefeller University, New York 10021, USA
    J Exp Med 186:2075-80. 1997
    b>TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine) is a new member of the TNF family that is induced upon T cell receptor engagement and activates c-Jun N-terminal kinase (JNK) after interaction with its putative ..
  19. ncbi Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene
    N Kim
    Laboratory of Immunology, The Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 97:10905-10. 2000
    Tumor necrosis factor-related, activation-induced cytokine (TRANCE), a tumor necrosis factor family member, mediates survival of dendritic cells in the immune system and is required for osteoclast differentiation and activation in the ..
  20. ncbi Mechanical inhibition of RANKL expression is regulated by H-Ras-GTPase
    Janet Rubin
    Department of Medicine, Emory University School of Medicine and Veterans Affairs Medical Center, Atlanta, Georgia 30033, USA
    J Biol Chem 281:1412-8. 2006
    ..We here investigate proximal events leading to the ERK1/2 activation that is required for mechanical repression of RANKL (receptor activator of NF-kappaB ligand) expression, the factor that controls local recruitment of osteoclasts...
  21. ncbi T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma
    H Takayanagi
    Department of Immunology, Faculty of Medicine and Graduate School of Medicine, University of Tokyo, Japan
    Nature 408:600-5. 2000
    Bone resorption is regulated by the immune system, where T-cell expression of RANKL (receptor activator of nuclear factor (NF)-kappaB ligand), a member of the tumour-necrosis factor family that is essential for osteoclastogenesis, may ..
  22. ncbi A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
    D M Anderson
    Department of Molecular Biology, Immunex Corporation, Seattle, Washington 98101, USA
    Nature 390:175-9. 1997
    ..of NF-kappaB), a new member of the TNFR family derived from dendritic cells, and the isolation of a RANK ligand (RANKL) by direct expression screening...
  23. ncbi TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis
    A R Pettit
    Beth Israel Deaconess Medical Center, New England Baptist Bone and Joint Institute, Harvard Institutes of Medicine, Boston, Massachusetts 02115, USA
    Am J Pathol 159:1689-99. 2001
    ..factor-related activation-induced cytokine, also known as receptor activator of nuclear factor-kappaB ligand (TRANCE/RANKL) is an essential factor for osteoclast differentiation...
  24. ncbi Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE
    D Kim
    Laboratory of Immunology, The Rockefeller University, New York, New York 10021, USA
    J Exp Med 192:1467-78. 2000
    Proper lymph node (LN) development requires tumor necrosis factor-related activation-induced cytokine (TRANCE) expression...
  25. ncbi Amelioration of bone loss in collagen-induced arthritis by neutralizing anti-RANKL monoclonal antibody
    Seiji Kamijo
    Department of Immunology, Juntendo University School of Medicine, Bunkyo ku, Tokyo, Japan
    Biochem Biophys Res Commun 347:124-32. 2006
    Receptor activator of NF-kappaB (RANK) and its ligand (RANKL) are pivotal regulators of osteoclast differentiation. RANK and RANKL also mediate T cell/dendritic cell (DC) interaction...
  26. ncbi Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation
    Donald A Glass
    Department of Molecular and Human Genetics, Bone Disease Program of Texas, Houston, 77030, USA
    Dev Cell 8:751-64. 2005
    ....
  27. ncbi TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
    B R Wong
    The Rockefeller University, New York, New York 10021, USA
    J Biol Chem 272:25190-4. 1997
    A novel member of the tumor necrosis factor (TNF) cytokine family, designated TRANCE, was cloned during a search for apoptosis-regulatory genes using a somatic cell genetic approach in T cell hybridomas...
  28. ncbi Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone
    Mandeep S Virk
    Department of Orthopaedic Surgery, The New England Musculoskeletal Institute, University of Connecticut Health Center, Farmington, CT 06030 5456, USA
    Bone 44:160-7. 2009
    ..In this study, we investigated the effect of simultaneous blockade of BMP pathway and RANK/RANKL axis in an osteolytic prostate cancer lesion in bone...
  29. ncbi Monokine induced by interferon-gamma is induced by receptor activator of nuclear factor kappa B ligand and is involved in osteoclast adhesion and migration
    Han Bok Kwak
    National Research Laboratory for Bone Metabolism, College of Dentistry, Chosun University, Gwangju, Korea
    Blood 105:2963-9. 2005
    ..The osteoclast differentiation process requires receptor activator of nuclear factor kappa B (NF-kappa B) ligand (RANKL), which causes complex changes in the expression of various genes...
  30. ncbi Interaction between angiotensin II, osteoprotegerin, and peroxisome proliferator-activated receptor-gamma in abdominal aortic aneurysm
    Corey S Moran
    Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Queensland, Australia
    J Vasc Res 46:209-17. 2009
    Osteoprotegerin (OPG) has been associated with abdominal aortic aneurysm (AAA) expansion. Angiotensin II (AngII) receptor blockade has been shown to reduce OPG expression in human AAA tissue...
  31. ncbi The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis
    Teiji Wada
    Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Dr Bohrgasse 3 5, A 1030 Vienna, Austria
    Nat Med 11:394-9. 2005
    ..Receptor activator of NF-kappaB (RANK) and its ligand RANKL have been identified as essential factors involved in osteoclast development and bone remodeling, but their ..
  32. ncbi RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis
    Jin Gohda
    Division of Cellular and Molecular Biology, Department of Cancer Biology, The Institute of Medical Science, The University of Tokyo, Shirokane dai, Minato ku, Tokyo, Japan
    EMBO J 24:790-9. 2005
    ..These results suggest that RANK may harbor a specific domain that amplifies TRAF6 signaling...
  33. ncbi Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis
    Yalei Wu
    University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    Arthritis Rheum 52:3257-68. 2005
    ..This study was undertaken to explore the roles of hyperproliferating synovial fibroblasts and macrophages in abnormal osteoclast formation, using the recently described BXD2 mouse model of RA...
  34. ncbi Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways
    Masanobu Tsubaki
    Division of Pharmacotherapy, Kinki University School of Pharmacy, 3 4 1, Kowakae, Higashi Osaka, Osaka 577 8502, Japan
    Mol Cell Biochem 304:53-60. 2007
    ..In the present study, our group investigated the mechanism by which RANKL expression is induced by MIP-1alpha and the effects of MIP-1alpha on the activation of osteoclasts...
  35. ncbi Receptor activator of NF-kappa B ligand and osteoprotegerin regulate proinflammatory cytokine production in mice
    Kenta Maruyama
    Department of Microbiology and Immunology, School of Medicine, Keio University, Tokyo, Japan
    J Immunol 177:3799-805. 2006
    Receptor activator of NF-kappaB ligand (RANKL) is a membrane-bound or soluble cytokine essential for osteoclast differentiation, whereas the decoy receptor osteoprotegerin (OPG) masks RANKL activity...
  36. ncbi RANKL-induced down-regulation of CX3CR1 via PI3K/Akt signaling pathway suppresses Fractalkine/CX3CL1-induced cellular responses in RAW264.7 cells
    Yurika Saitoh
    Division of Pathogenic Biochemistry, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama 930 0194, Japan
    Biochem Biophys Res Commun 364:417-22. 2007
    The receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation. In this study, we examined the effects of RANKL on chemokine receptor expression in osteoclast precursor cells, RAW264.7 cells...
  37. ncbi Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, WA, USA
    BMC Cancer 7:148. 2007
    ..Administration of osteoprotegerin (OPG) blocks these increases, indicating the critical role of RANKL in osteolysis in this model...
  38. ncbi Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2
    Nam Shik Kim
    Division of Molecular and Life Sciences, Pohang University of Science and Technology, Pohang 790 783, Kyungbuk, South Korea
    Mol Cell Biol 26:1002-13. 2006
    Receptor activator of NF-kappaB ligand (RANKL) is a key regulator for mammary gland development during pregnancy. RANKL-deficient mice display impaired development of lobulo-alveolar mammary structures...
  39. ncbi Osteoporotic bone formation in mice lacking tob2; involvement of Tob2 in RANK ligand expression and osteoclasts differentiation
    Rieko Ajima
    The Institute of Medical Science, University of Tokyo, 4 6 1, Shirokanedai, Minato ku, Tokyo 108 8639, Japan
    FEBS Lett 582:1313-8. 2008
    ..Furthermore, expression of RANKL mRNA in stromal cells was increased in the absence of Tob2 and decreased in the presence of Tob2...
  40. ncbi The role of nitric oxide in the mechanical repression of RANKL in bone stromal cells
    Jill Rahnert
    Applied Physiology, Georgia Institute of Technology College of Sciences, Atlanta GA 30332, USA
    Bone 43:48-54. 2008
    ..At the same time, strain causes decreased expression of RANKL, a factor critical for osteoclastogenesis...
  41. ncbi Osteoclasts are dispensable for hematopoietic stem cell maintenance and mobilization
    Kana Miyamoto
    Department of Orthopedic Surgery, Keio Kanrinmaru Project, Keio University School of Medicine, Shinjuku ku, Tokyo, Japan
    J Exp Med 208:2175-81. 2011
    ..activity in three osteopetrotic mouse models: op/op, c-Fos-deficient, and RANKL (receptor activator of nuclear factor kappa B ligand)-deficient mice...
  42. ncbi Epidermal receptor activator of NF-kappaB ligand controls Langerhans cells numbers and proliferation
    Jean Baptiste O Barbaroux
    St John s Institute of Dermatology, King s College London, London, United Kingdom
    J Immunol 181:1103-8. 2008
    ..The TNF superfamily member receptor activator of NF-kappaB ligand (RANKL, TNFSF11) has been shown to sustain viability of blood dendritic cells in addition to its role in promoting proliferation ..
  43. ncbi Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells
    Karin Loser
    Department of Dermatology, University of Munster, D 48149 Munster, Germany
    Nat Med 12:1372-9. 2006
    ..Receptor activator of NF-kappaB (RANK) and its ligand (RANKL; also known as CD254, OPGL and TRANCE) are key regulators of bone remodeling, mammary gland formation, lymph node development and T-cell/dendritic cell ..
  44. ncbi YY1 is involved in RANKL-induced transcription of the tartrate-resistant acid phosphatase gene in osteoclast differentiation
    Zhenqi Shi
    Department of Pathology, University of Alabama at Birmingham, 1670 University Blvd, VH G046B, Birmingham, AL 35294, USA
    Gene 343:117-26. 2004
    Receptor activator of nuclear factor kappa B (NF-kappaB) ligand (RANKL), a critical activator of osteoclast differentiation, plays a pivotal role in tartrate-resistant acid phosphatase (TRAP) gene expression...
  45. ncbi NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism
    Zhenqiang Yao
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA
    J Clin Invest 119:3024-34. 2009
    TNF and RANKL mediate bone destruction in common bone diseases, including osteoarthritis and RA. They activate NF-kappaB canonical signaling directly in osteoclast precursors (OCPs) to induce osteoclast formation in vitro...
  46. ncbi Involvement of upstream stimulatory factors 1 and 2 in RANKL-induced transcription of tartrate-resistant acid phosphatase gene during osteoclast differentiation
    Yi Liu
    Department of Pathology, The University of Alabama, Birmingham, Alabama 35294, USA
    J Biol Chem 278:20603-11. 2003
    ..TRAP expression in osteoclasts is regulated by receptor activator of NF-kappaB (RANKL), a potent activator of osteoclast differentiation...
  47. ncbi IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance
    Erik Lubberts
    Rheumatology and Advanced Therapeutics, University Medical Center Nijmegen, Nijmegen, The Netherlands
    J Immunol 170:2655-62. 2003
    ..joint of type II collagen-immunized mice on bone erosion and synovial receptor activator of NF-kappa B ligand (RANKL)/receptor activator of NF-kappa B/osteoprotegerin (OPG) expression...
  48. ncbi Overexpression of RANKL implicates IFN-beta-mediated elimination of B-cell precursors in the osteopetrotic bone of microphthalmic mice
    K Roundy
    Division of Cell Biology and Immunology, Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah 84132, USA
    J Bone Miner Res 18:278-88. 2003
    ..Surprisingly, the expression of a subset of such genes including RANKL, stromal-derived factor (SDF-1), B-cell lymphotactin chemokine (BLC), and RANK was dramatically enhanced in the mi ..
  49. ncbi Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction
    Eilidh Williamson
    Department of Inflammation, Immunex Corp, Seattle WA 98101, USA
    J Immunol 169:3606-12. 2002
    ..expression and function of the TNFR family member receptor activator of NF-kappaB (RANK) and its cognate ligand, RANKL, in vitro and in vivo...
  50. ncbi Osteoprotegerin expression and sensitivity in otosclerosis with different histological activity
    Tamás Karosi
    Department of Otolaryngology and Head and Neck Surgery, Medical and Health Science Center, University of Debrecen, Nagyerdei krt 98, Debrecen 4032, Hungary
    Eur Arch Otorhinolaryngol 268:357-65. 2011
    ..in part, be considered as an autoimmune-inflammatory disease, disturbed balance of TNF-alpha and osteoprotegerin (OPG) expression has been implicated in the pathological bone remodeling...
  51. ncbi Lymphotoxin signal promotes thymic organogenesis by eliciting RANK expression in the embryonic thymic stroma
    Yasuhiro Mouri
    Division of Molecular Immunology, Institute for Enzyme Research, The University of Tokushima, Tokushima 770 8503, Japan
    J Immunol 186:5047-57. 2011
    ..Thus, the LTβR signal exhibits a novel and unique function in promoting RANK activity for mTEC organization, indicating a link between thymic organogenesis mediated by multiple cytokine signals and the control of autoimmunity...
  52. ncbi Prominent bone loss mediated by RANKL and IL-17 produced by CD4+ T cells in TallyHo/JngJ mice
    Hee Yeon Won
    Division of Life and Pharmaceutical Sciences, College of Pharmacy, Center for Cell Signaling and Drug Discovery Research, Ewha Womans University, Seoul, Korea
    PLoS ONE 6:e18168. 2011
    ..and osteoprotegerin were decreased in TH mice, whereas osteoclast-driven bone resorption markers such as IL-6 and RANKL were significantly elevated in the bone marrow and blood of TH mice...
  53. ncbi The mouse RANKL gene locus is defined by a broad pattern of histone H4 acetylation and regulated through distinct distal enhancers
    Melissa L Martowicz
    Department of Biochemistry, University of Wisconsin Madison, Madison, Wisconsin 53706, USA
    J Cell Biochem 112:2030-45. 2011
    b>RANKL is a stromal cell-derived tumor necrosis factor (TNF)-like factor that plays a primary role in osteoclast formation and function...
  54. ncbi Defective Fas ligand expression and activation-induced cell death in the absence of IL-2-inducible T cell kinase
    Andrew T Miller
    Department of Pathology, Program in Immunology and Virology, University of Massachusetts Medical Center, 55 Lake Avenue North, Worcester, MA 01655, USA
    J Immunol 168:2163-72. 2002
    ..Together these studies define an important role for Itk in TCR signaling, leading to cytokine gene expression and activation-induced cell death...
  55. ncbi The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development
    J E Fata
    Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Canada
    Cell 103:41-50. 2000
    Osteoprotegerin-ligand (OPGL) is a key osteoclast differentiation/activation factor essential for bone remodeling...
  56. ncbi Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis
    Takehiko Matsushita
    Department of Orthopaedics, Case Western Reserve University, 2109 Adelbert Road, BRB 329, Cleveland, OH 44106, USA
    Mol Cell Biol 29:5843-57. 2009
    ..Furthermore, inactivation of ERK1 and ERK2 significantly reduced RANKL expression, accounting for a delay in osteoclast formation...
  57. ncbi The role of RANKL (TRANCE/TNFSF11), a tumor necrosis factor family member, in skeletal development: effects of gene knockout and transgenic rescue
    Paul R Odgren
    Department of Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA
    Connect Tissue Res 44:264-71. 2003
    We report the skeletal manifestations of restoring RANKL (TNFSF11/TRANCE; see foot note on nomenclature) expression in null mice using a lymphocyte-specific promoter...
  58. ncbi Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling
    Cécile Mazière
    INSERM ERI 12, Amiens, France
    J Cell Physiol 221:572-8. 2009
    ..In the current studies, the effect of Cu(2+)-oxidized LDL (OxLDL) on RANKL-induced RAW264...
  59. ncbi Down-regulation of mTOR leads to up-regulation of osteoprotegerin in bone marrow cells
    Makio Mogi
    Department of Medicinal Biochemistry, School of Pharmacy, Aichi Gakuin University, Nagoya, Aichi, Japan
    Biochem Biophys Res Commun 384:82-6. 2009
    Osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor regulates bone mass by inhibiting osteoclastic bone resorption...
  60. ncbi Opg, Rank, and Rankl in tooth development: co-ordination of odontogenesis and osteogenesis
    A Ohazama
    Department of Craniofacial Development, Floor 28, Guy s Tower, GKT Dental Institute, King s College London, Guy s Hospital, London Bridge, London SE1 9RT, UK
    J Dent Res 83:241-4. 2004
    Osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) are mediators of various cellular interactions, including bone metabolism...
  61. ncbi Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice
    Sean Morony
    Department of Molecular Cellular and Integrative Physiology, University of California, Los Angeles, USA
    Circulation 117:411-20. 2008
    ..However, genetic and treatment studies in mice suggest that osteoprotegerin may protect against vascular calcification...
  62. ncbi The expression of osteoprotegerin is required for maintaining the intervertebral disc endplate of aged mice
    Qian Qian Liang
    Department of Orthopaedics and Traumatology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, PR China
    Bone 48:1362-9. 2011
    Human chondrocytes and annulus fibrosus cells of intervertebral disc (IVD) express osteoprotegerin (OPG), but the effect of OPG on the pathogenesis of IVD degeneration remains unknown...
  63. ncbi Streptococcus pyogenes infection induces septic arthritis with increased production of the receptor activator of the NF-kappaB ligand
    Atsuo Sakurai
    Department of Oral and Molecular Microbiology, Osaka University Graduate School of Dentistry, 1 8 Yamadaoka, Suita Osaka 565 0871, Japan
    Infect Immun 71:6019-26. 2003
    ..We noted that an increase in the amount of receptor activator of NF-kappaB ligand (RANKL), which is a key cytokine in osteoclastogenesis, was also evident in the joints of the infected mice...
  64. ncbi Lymphotoxin-independent expression of TNF-related activation-induced cytokine by stromal cells in cryptopatches, isolated lymphoid follicles, and Peyer's patches
    Rebekah T Taylor
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, 615 Michael Street, Atlanta, GA 30322, USA
    J Immunol 178:5659-67. 2007
    ..in CP and ILF of adult mice also expressed FDC-M1, CD157 (BP-3), and TNF-related activation-induced cytokine (TRANCE)...
  65. ncbi RANKL-stimulated TNFalpha production in osteoclast precursor cells promotes osteoclastogenesis by modulating RANK signaling pathways
    Akihiro Nakao
    Section of Cellular Physiology, Department of Physiological Science and Molecular Biology, Fukuoka Dental College, 2 15 1 Tamura, Sawara ku, Fukuoka 814 0193, Japan
    Biochem Biophys Res Commun 357:945-50. 2007
    ..to be an important factor for bone resorption, particularly in inflammatory bone diseases, the relevance between RANKL and TNFalpha in osteoclastogenesis remains unclear...
  66. ncbi LTbetaR signaling induces cytokine expression and up-regulates lymphangiogenic factors in lymph node anlagen
    Mark F Vondenhoff
    Department of Molecular Cell Biology and Immunology, VU Vrije Universiteit University Medical Center, Amsterdam, The Netherlands
    J Immunol 182:5439-45. 2009
    ..occurs independently of LTalpha and that these cells, expressing TNF-related activation-induced cytokine (TRANCE), are the earliest LTi cells. By paracrine signaling the first expression of LTalpha(1)beta(2) is induced...
  67. ncbi Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling
    Peter Pivonka
    University of Western Australia, WA 6009, Australia
    J Theor Biol 262:306-16. 2010
    The RANK-RANKL-OPG system is an essential signaling pathway involved in bone cell-cell communication, with ample evidence that modification of the RANK-RANKL-OPG signaling pathway has major effects on bone remodeling...
  68. ncbi Receptor activator of nuclear factor-kappaB ligand-induced mouse osteoclast differentiation is associated with switching between NADPH oxidase homologues
    Hideyuki Sasaki
    Department of Stress Science, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima 770 8503, Japan
    Free Radic Biol Med 47:189-99. 2009
    Reactive oxygen species (ROS) have been suggested to regulate receptor activator of nuclear factor-kappaB ligand (RANKL)-stimulated osteoclast differentiation...
  69. ncbi Regulation of vacuolar H(+)-ATPase in microglia by RANKL
    Eric M Serrano
    Department of Orthodontics, University of Florida College of Dentistry, Gainesville, FL 32610, USA
    Biochem Biophys Res Commun 389:193-7. 2009
    ..The expression of a3 in osteoclasts requires stimulation by Receptor Activator of Nuclear Factor kappaB-ligand (RANKL). We found that Receptor Activator of Nuclear Factor kappaB (RANK) was expressed by microglia...
  70. ncbi Identification of LRRc17 as a negative regulator of receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast differentiation
    Taesoo Kim
    Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Biol Chem 284:15308-16. 2009
    ..from bone marrow precursors in response to osteotropic factors by inducing receptor activator of NF-kappaB ligand (RANKL) expression and down-regulating osteoprotegerin (OPG) production...
  71. ncbi Immunomodulation by blockade of the TRANCE co-stimulatory pathway in murine allogeneic islet transplantation
    Anne Wojtusciszyn
    Cell Isolation and Transplantation Center, University of Geneva School of Medicine, Geneva, Switzerland
    Transpl Int 22:931-9. 2009
    We explore herein the effect of TNF-related activation-induced cytokine (TRANCE) co-stimulatory pathway blockade on islet survival after allograft transplantation...
  72. ncbi ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency
    Aisha V Sauer
    San Raffaele Telethon Institute for Gene Therapy HSR TIGET, Milan, Italy
    Blood 114:3216-26. 2009
    ..These alterations are the combined result of an imbalanced receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin axis, causing decreased osteoclastogenesis and an intrinsic defect of osteoblast function with ..
  73. ncbi Enhanced expression and shedding of receptor activator of NF-kappaB ligand during tumor-bone interaction potentiates mammary tumor-induced osteolysis
    Kalyan C Nannuru
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198 5845, USA
    Clin Exp Metastasis 26:797-808. 2009
    ..Receptor activator of nuclear factor-kappaB (RANK) ligand (RANKL) is one of the critical signaling molecules involved in osteolysis and bone metastasis...
  74. ncbi Dehydroepiandrosterone inhibited the bone resorption through the upregulation of OPG/RANKL
    Yu Dong Wang
    Department of Obstetrics and Gynecology, The Sixth People s Hospital, Jiaotong University, Shanghai, China
    Cell Mol Immunol 3:41-5. 2006
    ..viability, regulation of DHEA on the expression of osteoprotegerin (OPG)/receptor activator of NF-kappaB ligand (RANKL) mRNA in OBs, and then observed the action of DHEA on bone resorption of OCs in the presence or absence of OBs...
  75. ncbi EBF2 regulates osteoblast-dependent differentiation of osteoclasts
    Matthias Kieslinger
    Gene Center and Institute for Biochemistry, University of Munich, 81377 Munich, Germany
    Dev Cell 9:757-67. 2005
    ..Taken together, these data identify EBF2 as a regulator of RANK-RANKL signaling and osteoblast-dependent differentiation of osteoclasts.
  76. ncbi A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL
    Wang Hui
    Musculoskeletal Research Group, The Medical School, University of Newcastle, Newcastle upon Tyne, UK
    Arthritis Res Ther 7:R57-64. 2005
    ..Furthermore, there was increased expression of RANK and its ligand RANKL in the inflammatory cells, in inflamed synovium and in articular cartilage of knee joints treated with the ..
  77. ncbi Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution
    Shuichiro Ito
    Biomedical Research Laboratories, Sankyo, CO, Ltd 1 2 58, Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    J Biol Chem 277:6631-6. 2002
    ..Receptor activator of NF-kappa B ligand (RANKL, also known as ODF and OPGL), a member of the tumor necrosis factor (TNF) family, triggers osteoclastogenesis by ..
  78. ncbi Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells
    Hisatomo Kondo
    Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    J Bone Miner Res 17:1667-79. 2002
    ..of osteoclast formation and activation, effects that are associated with reciprocal up- and down-regulation of RANKL and osteoprotegerin (OPG), respectively...
  79. ncbi Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis
    Kabsun Kim
    Medical Research Center for Gene Regulation, Chonnam National University Medical School, Gwangju, 501 746, Korea
    J Biol Chem 280:35209-16. 2005
    ..controlled by the tumor necrosis factor family member tumor necrosis factor-related activation-induced cytokine (TRANCE) via induction of various transcription factors, including nuclear factor of activated T cells (NFAT) c1...
  80. ncbi BSP and RANKL induce osteoclastogenesis and bone resorption synergistically
    Paloma Valverde
    Department of General Dentistry, Tufts University School of Dental Medicine, Boston, Massachusetts 02111, USA
    J Bone Miner Res 20:1669-79. 2005
    b>RANKL and BSP are upregulated in several bone resorptive disorders...
  81. ncbi Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis
    Zhiyuan Zhang
    Section of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Immunol 171:3620-6. 2003
    Receptor activator of NF-kappaB ligand (RANKL) is essential for differentiation and function of osteoclasts. The negative signaling pathways downstream of RANKL are not well characterized. By retroviral transduction of RAW264...
  82. ncbi Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis
    Saad Gad Kamel Mohamed
    Department of Internal Medicine, Toyama Medical and Pharmaceutical University, Sugitani 2630, Toyama 930 0194, Japan
    Biochem Biophys Res Commun 329:839-45. 2005
    ..were differentiated into osteoclasts in the presence of receptor activator of nuclear factor kappaB ligand (RANKL) and/or macrophage colony-stimulating factor...
  83. ncbi TIEG1 null mouse-derived osteoblasts are defective in mineralization and in support of osteoclast differentiation in vitro
    Malayannan Subramaniam
    Department of Biochemistry and Molecular Biology, 1601B Guggenheim Bldg, Mayo Clinic College of Medicine, 200 First Street S W, Rochester, MN 55905, USA
    Mol Cell Biol 25:1191-9. 2005
    ..Examination of gene expression in the TIEG(-/-) OBs revealed decreased RANKL and increased OPG expression compared to TIEG(+/+) OBs...
  84. ncbi RANK ligand expression in heat shock factor-2 deficient mouse bone marrow stromal/preosteoblast cells
    Hiroshi Kajiya
    Department of Physiological Science and Molecular Biology, Fukuoka Dental College, Sawara ku, Fukuoka, 814 0193, Japan
    J Cell Biochem 97:1362-9. 2006
    ..a functional role for heat shock factor-2 (HSF-2) in fibroblast growth factor-2 (FGF-2)-induced RANK ligand (RANKL), a critical osteoclastogenic factor expression on stromal/preosteoblast cells...
  85. ncbi Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis
    H Min
    Department of Biosystems Analysis, Amgen, Incorporated, Thousand Oaks, California 91320, USA
    J Exp Med 192:463-74. 2000
    ..Although OPG is normally expressed in arteries, OPG ligand (OPGL) and receptor activator of NF-kappaB (RANK) are not detected in the arterial walls of wild-type adult mice...
  86. ncbi Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice
    Jay Cao
    Division of Endocrinology, Veterans Affairs Medical Center, San Francisco, California 94121, USA
    J Bone Miner Res 18:270-7. 2003
    Osteoblasts regulate the recruitment and activity of osteoclasts through expression of RANKL and osteoprotegerin (OPG)...
  87. ncbi Epigenetic control of mouse receptor activator of NF-kappa B ligand gene expression
    Sohei Kitazawa
    Division of Molecular Pathology, Department of Biomedical Informatics, Kobe University Graduate School of Medicine, 7 5 1 Kusunoki cho, Chuo Ku, Kobe 650 0017, Japan
    Biochem Biophys Res Commun 293:126-31. 2002
    Receptor activator of NF-kappa B ligand (RANKL) is a membrane-bound signal transducer requisite for differentiation and maintenance of osteoclasts...
  88. ncbi Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway
    Hao Huang
    BK21 Program, Seoul National University, Seoul 110 749, Republic of Korea
    Biochem Biophys Res Commun 351:99-105. 2006
    ..activated T cells (NFAT) c1 by receptor activator of nuclear factor kappaB ligand (RANKL), the key osteoclast differentiation factor. Overexpression of dominant-negative forms of p38 upstream kinases MKK3 and MKK6 elicited similar ..
  89. ncbi Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand
    Atsuhiko Hikita
    Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 0033, USA
    J Biol Chem 281:36846-55. 2006
    Receptor activator of NF-kappaB ligand (RANKL) is a transmembrane glycoprotein that has an essential role in the development of osteoclasts...
  90. ncbi Essential role for ADAM19 in cardiovascular morphogenesis
    Hong Ming Zhou
    Cell Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Cell Biol 24:96-104. 2004
    ..Most adam19(-/-) animals die perinatally, likely as a result of their cardiac defects. These findings raise the possibility that mutations in ADAM19 may contribute to human congenital heart valve and septal defects...
  91. ncbi CMRF-35-like molecule-1, a novel mouse myeloid receptor, can inhibit osteoclast formation
    Dong Hui Chung
    Veterans Administration Medical Center and University of California, San Francisco, CA 94121, USA
    J Immunol 171:6541-8. 2003
    ..Expression of CLM-1 mRNA is down-regulated by treatment with receptor activator of NF-kappaB ligand (RANKL), a cytokine that drives osteoclast formation...
  92. ncbi Evidence that receptor activator of nuclear factor (NF)-kappaB ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kappaB-independent and TRAF6-dependent mechanism
    Alok C Bharti
    Cytokine Research Section, Department of Bioimmunotherapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 279:6065-76. 2004
    The receptor activator of NF-kappaB ligand (RANKL), a recently identified member of the tumor necrosis factor (TNF) superfamily, has been shown to induce osteoclastogenesis and dendritic cell survival...
  93. ncbi Inhibition of Wnt signaling by the osteoblast-specific transcription factor Osterix
    Chi Zhang
    Department of Molecular Genetics, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 105:6936-41. 2008
    ..Our results add a layer of control to Wnt/beta-catenin signaling in bone...
  94. ncbi p44/42 MAPK activation is necessary for receptor activator of nuclear factor-kappaB ligand induction by high extracellular calcium
    Yong Hee Kim
    Department of Pharmacology and Dental Therapeutics, College of Dentistry, Dental Research Institute, Seoul National University, Seoul, Republic of Korea
    Biochem Biophys Res Commun 304:729-35. 2003
    ..of high Ca(2+)(o) that are responsible for controlling the expression of receptor activator of NF-kappaB ligand (RANKL) in mouse osteoblastic cells. As previously reported, high Ca(2+)(o) increased RANKL expression...
  95. ncbi Regulation of activation-induced receptor activator of NF-kappaB ligand (RANKL) expression in T cells
    Ruoxiang Wang
    Department of Immunology, Jerome H Holland Laboratory, American Red Cross, Rockville, USA
    Eur J Immunol 32:1090-8. 2002
    Receptor activator of NF-kappaB ligand (RANKL) is a type II membrane protein of the TNF family and plays a critical role in the regulation of osteoclastogenesis...
  96. ncbi Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of NFkappa B
    David Cappellen
    Novartis Pharma Research, Arthritis and Bone Metabolism Therapeutic Area, CH 4002 Basel, Switzerland
    J Biol Chem 277:21971-82. 2002
    Cytokines macrophage colony stimulating factor (M-CSF) and the receptor activator of NFkappaB ligand (RANKL) induce differentiation of bone marrow hematopoietic precursor cells into bone-resorbing osteoclasts without the requirement for ..
  97. ncbi Metabolic acidosis stimulates RANKL RNA expression in bone through a cyclo-oxygenase-dependent mechanism
    Kevin K Frick
    Department of Medicine, Nephrology Unit, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Bone Miner Res 18:1317-25. 2003
    ..To determine whether acidosis alters expression of RNA for the osteoclastic differentiation factor RANKL, mouse calvariae were incubated in neutral or physiologically acidic media...
  98. ncbi Association of sustained ERK activity with integrin beta3 induction during receptor activator of nuclear factor kappaB ligand (RANKL)-directed osteoclast differentiation
    Hong Hee Kim
    National Research Laboratory for Bone Metabolism, Department of Microbiology and Immunology, College of Medicine, Chosun University, Gwangju 501 759, Korea
    Exp Cell Res 289:368-77. 2003
    ..family, we found that radicicol increased cell fusion during receptor activator of nuclear factor kappaB ligand (RANKL)-driven differentiation of osteoclasts at concentrations far below the ones shown to inhibit its targets in ..
  99. ncbi Porphyromonas gingivalis induces receptor activator of NF-kappaB ligand expression in osteoblasts through the activator protein 1 pathway
    Nobuo Okahashi
    Department of Oral Frontier Biology, Osaka University Graduate School of Dentistry, Osaka Suita 565 0871, Japan
    Infect Immun 72:1706-14. 2004
    ..gingivalis induced receptor activator of nuclear factor kappaB (NF-kappaB) ligand (RANKL) mRNA expression in mouse primary osteoblasts...
  100. ncbi Osteoclastogenesis during mouse tooth germ development is mediated by receptor activator of NFKappa-B ligand (RANKL)
    Tomotaka Suzuki
    Maxillofacial Orthognathics, Department of Maxillofacial Reconstruction and Function, Division of Maxillofacial Neck Reconstruction, Graduate School, Tokyo Medical and Dental University, 1 5 45 Yushima, Bunkyo ku, Tokyo 113 8549, Japan
    J Bone Miner Metab 22:185-91. 2004
    ..Recently, the signaling of receptor activator of nuclear factor-KappaB (RANK) and its ligand (RANKL) was reported to play a pivotal role in osteoclast formation and activation...
  101. ncbi RANKL treatment releases the negative regulation of the poly(ADP-ribose) polymerase-1 on Tcirg1 gene expression during osteoclastogenesis
    Guillaume E Beranger
    GéPITOS K2943 CNRS UNSA, Faculté de Médecine de l Université de Nice Sophia Antipolis, Nice, France
    J Bone Miner Res 21:1757-69. 2006
    ..Using the mouse osteoclastic model RAW264.7 cells, we studied Tcirg1 gene expression, and we identified PARP-1 as a transcriptional repressor negatively regulated by RANKL during osteoclastogenesis.

Research Grants43

  1. BONE MATRIX AND BONE RESORPTION
    Paul R Odgren; Fiscal Year: 2010
    ..This proposal aims to investigate new genes that regulate the formation and activity of osteoclasts to better understand bone biology in general, and potentially to find new ways to treat these widespread bone disorders. ..
  2. BONE MATRIX AND BONE RESORPTION
    PAUL ODGREN; Fiscal Year: 2006
    ..This method will also permit us to follow the persistence of abnormal expression or its return to normal following restoration of resorption by cytokine treatments. ..
  3. SACRAL CREST CELLS AND ENTERIC NEURODEVELOPMENT
    Raj Kapur; Fiscal Year: 2005
    ..The results of this study will further our understanding of normal enteric neurodevelopment and congenital disorders of intestinal motility. ..
  4. TRANCE REGULATION OF CHONDROCYTE MATURATION
    PAUL ODGREN; Fiscal Year: 2005
    ..Adapted from the Investigator's Abstract): This project will investigate the hypothesis that the growth factor TRANCE directly regulates both cartilage maturation and bone growth in the appendicular and craniofacial skeleton using ..
  5. Combinatorial Protein Transfer for Cancer Therapeutics
    Aoshuang Chen; Fiscal Year: 2006
    ..abstract_text> ..
  6. MOLECULAR CONTROL OF RANKL GENE EXPRESSION
    CHARLES O BRIEN; Fiscal Year: 2007
    ..The key mechanism by which these stromal/osteoblastic cells support osteoclastogenesis is expression of RANKL (receptor activator of NFkappaB ligand)...
  7. MOLECULAR CONTROL OF RANKL GENE EXPRESSION
    CHARLES A O apos BRIEN; Fiscal Year: 2010
    ..by which stromal cells support osteoclast differentiation is expression of receptor activator of NF(B ligand (RANKL)...
  8. BONE MATRIX AND BONE RESORPTION
    PAUL ODGREN; Fiscal Year: 2009
    ....
  9. MOLECULAR CONTROL OF RANKL GENE EXPRESSION
    CHARLES O BRIEN; Fiscal Year: 2009
    ..by which stromal cells support osteoclast differentiation is expression of receptor activator of NF(B ligand (RANKL)...
  10. Individual Predoctoral Dental Scientist Fellowship
    Cameron Walker; Fiscal Year: 2007
    ..resorption of large volumes of bone, preliminary studies from our laboratory have suggested that neither RANKL nor inflammatory cytokines play a significant role in physiological tooth movement...
  11. IN VIVO REGULATION OF IL6 AND IL6R GENE EXPRESSION
    CHARLES O BRIEN; Fiscal Year: 2002
    ..Finally, cis-acting regulatory elements in the IL-6 promoter that are the targets for estrogen and PTH actions in vivo will be identified. ..